

Diaceutics PLC - Board Change Update

Belfast and London, 29 October 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, today announces that following the announcement on 1 October 2024 and completion of the usual Nominated Adviser due diligence checks, Cheryl MacDiarmid is confirmed as having joined the board as a Non-Executive Director.

The following information is disclosed in accordance with Schedule 2(g) of the AIM Rules for Companies:

Additional information with regard to Cheryl MacDiarmid:

Cheryl MacDiarmid (née Gaskin), age 56, is currently or has been a director of the following companies within the past five years:

Current Directorships

Allergy Therapeutics Plc

Former Directorships

Phivco UK Limited
ViiV Healthcare UK (NO.6) Limited
ViiV Healthcare UK (NO.3) Limited
ViiV Healthcare UK (NO.5) Limited
ViiV Healthcare Trading Services UK Limited
ViiV Healthcare UK (NO.4) Limited
ViiV Healthcare Overseas Limited
ViiV Healthcare UK (NO.7) Limited
ViiV Healthcare Finance Limited
ViiV Healthcare UK Limited
Phivco UK II Limited

Enquiries:

Diaceutics PLC

Ryan Keeling, Chief Executive Officer
Nick Roberts, Chief Financial Officer

Tel: +44 (0)28 9040 6500
investorrelations@diaceutics.com

Canaccord Genuity Limited (Nomad & Broker)

Simon Bridges, Andrew Potts, Harry Rees

Tel: +44 (0)20 7523 8000

Alma Strategic Communications

Caroline Forde, Kinvara Verdon

Tel: +44(0)20 3405 0205
diaceutics@almastrategic.com

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAFEMFSUEELSEES